Investors

Investors

Company Profile

The Genelux Difference

Genelux is a Phase 3 biopharmaceutical company developing powerful therapeutics for patients suffering from difficult-to-treat cancers. The Company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor’s sophisticated defense mechanisms.

Equiniti Trust Company LLC (EQ)

Reference: Genelux Corp.

PO Box 500

Newark, NJ 07101

Assistance Online:

https://equiniti.com/us/ast-access/individuals

Contact an EQ representative:

(800) 937-5449 or (718) 921-8124

Email EQ from the website by selecting GET HELP.